Orbit Genomics’ prototype lung cancer test, demonstrated unparalleled accuracy for diagnosing lung cancer in a peer reviewed pilot study.
BOULDER, COLORADO, UNITED STATES, January 6, 2022 /EINPresswire.com/ — Orbit Genomics, Inc., an early-stage genomics company, today announced that it has received $3 million in funding to launch its first product, OrbiSeq™ – L, a lung cancer diagnostic test which demonstrated significantly higher accuracy than any test currently marketed. The lead investors for this round are NHH Ventures and New Horizon Health Ltd (6606-HK). The company is raising an additional $1 million to complete the $4 million round. It also entered into an exclusive licensing agreement with New Horizon Health Ltd to market Orbit Genomics’ products in Asia.
Orbit Genomics’ patent pending OrbiSeq platform analyzes novel markers in blood or saliva that uniquely reflect both inherited disease risk and risk acquired from lifestyle and environmental exposures. It can be applied to diagnose, treat, and help prevent complex diseases including cancer, heart disease and neurological diseases.
In a published pilot study, OrbiSeq – L demonstrated 93% Sensitivity/97% Specificity for diagnosing lung cancer, the world’s deadliest cancer that killed 1.8 million people in 2020. Low dose computed tomography (LDCT) is used for diagnosis, but often requires a biopsy for confirmation. It’s estimated that OrbiSeq-L could potentially avoid 500,000 unnecessary biopsies annually in the United States, saving ~$5 billion in procedure costs.